 | • レポートコード：MRC2106A055 • 出版社/出版日：Mordor Intelligence / 2021年5月20日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、超崩壊剤の世界市場について調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（天然超崩壊剤、合成超崩壊剤、その他）分析、製剤別（タブレット、カプセル）分析、治療別（神経疾患、消化器疾患、腫瘍、その他）分析、地域別分析、競争状況、市場機会・未来動向などを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・超崩壊剤の世界市場規模：製品別（天然超崩壊剤、合成超崩壊剤、その他） ・超崩壊剤の世界市場規模：製剤別（タブレット、カプセル） ・超崩壊剤の世界市場規模：治療別（神経疾患、消化器疾患、腫瘍、その他） ・超崩壊剤の世界市場規模：地域別 ・競争状況 ・市場機会・未来動向 |
The superdisintegrants market studied was expected to grow with a CAGR of approximately 8.1% over the forecast period. The major factors accrediting to the growth of the market are increasing adoption of orally disintegrating tablets, and increasing healthcare expenditure and awareness. Furthermore, the increasing number of pediatric patients and the geriatric population cannot swallow solid forms of medication. These agents are used as a viscosity-improving agent in drug-loaded films, having improved performance, and maintains high drug content uniformity. Superdisintegrants are added to solid dosage forms such as capsules or tablets that aids them to disintegrate when submerged in liquid. Due to this benefit, these are significantly used in the manufacturing of disintegrating oral formulations, which further increases the demand for superdisintegrants in the market. However, the concerns related to safety and quality are the major drawback of market growth.
Key Market Trends
Natural Superdisintegrants segment to register significant growth
– Natural superdisintegrants such as ispaghulla, gellan gum, fenugreek seed mucilage, and gum karaya, among others have many advantages over synthetic superdisintegrants, such as biodegradability, chemical inertness, and non-toxicity. Moreover, it can be modified in several ways in order to obtain tailor-made materials for drug delivery systems that aim to enhance safety by the formulation of an accessible dosage.
– The major factors propelling the segment growth are the increasing number of pediatric patients and the geriatric population, expansion of generic drugs market, increase of new superdisintegrants.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall superdisintegrants market, throughout the forecast period. The market growth is due to factors such as the presence of key players, established healthcare infrastructure, and availability of funding for research and development for advanced drug delivery methods. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region, the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market
Competitive Landscape
The Superdisintegrants market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market BASF SE, Ashland Global Holdings Inc., DuPont., Roquette Freres, DFE Pharma, JRS Pharma, Asahi Kasei Corporation, Merck KGaA, and Corel Pharma Chem.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Adoption of Orally Disintegrating Tablets
4.2.2 Increase Healthcare Expenditure and Awareness
4.2.3 Rising Prevalence Of Chronic Conditions With Increasing Number Of Pediatric And Geriatric Population
4.3 Market Restraints
4.3.1 Concerns About the Safety and Quality of Product
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Natural Superdisintegrants
5.1.2 Synthetic Superdisintegrants
5.1.2.1 Modified Starch
5.1.2.2 Modified Cellulose
5.1.2.3 Crospovidone
5.1.2.4 Calcium Silicates
5.1.2.5 Ion Exchange Resins
5.1.3 Others
5.2 By Formulation
5.2.1 Tablets
5.2.2 Capsules
5.3 By Therapeutic Area
5.3.1 Neurological Diseases
5.3.2 Gastrointestinal Diseases
5.3.3 Oncology
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 BASF SE
6.1.2 Ashland Global Holdings Inc.
6.1.3 DuPont
6.1.4 Roquette Freres
6.1.5 DFE Pharma
6.1.6 JRS Pharma
6.1.7 Asahi Kasei Corporation
6.1.8 Merck KGaA
6.1.9 Corel Pharma Chem
7 MARKET OPPORTUNITIES AND FUTURE TRENDS